IS-741 (Ishihara Sangyo).

  • Claudio Bassi
  • Published 2001 in Current opinion in investigational drugs

Abstract

IS-741 is a phospholipase A2 (PLA2) inhibitor under development by Ishihara Sangyo Kaisha and Sumitomo as a potential treatment for pancreatitis 1187575]. Sumitomo is developing the drug in phase II trials for acute pancreatitis 13990261. In an animal model, IS-741 has been shown to prevent pancreatitis-associated lung injury following endotoxemia [337503].

Cite this paper

@article{Bassi2001IS741S, title={IS-741 (Ishihara Sangyo).}, author={Claudio Bassi}, journal={Current opinion in investigational drugs}, year={2001}, volume={2 4}, pages={510-2} }